• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

作者信息

McKinnell James A, Dwyer Jamie P, Talbot George H, Connolly Lynn E, Friedland Ian, Smith Alex, Jubb Adrian M, Serio Alisa W, Krause Kevin M, Daikos George L

机构信息

Los Angeles Biomedical Research Institute, Los Angeles, CA

Vanderbilt University Medical Center, Nashville, TN.

出版信息

N Engl J Med. 2019 Feb 21;380(8):791-793. doi: 10.1056/NEJMc1807634.

DOI:10.1056/NEJMc1807634
PMID:30786196
Abstract
摘要

相似文献

1
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.普拉佐米星用于治疗耐碳青霉烯类肠杆菌科细菌引起的感染。
N Engl J Med. 2019 Feb 21;380(8):791-793. doi: 10.1056/NEJMc1807634.
2
A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. Hartford 医院氨基糖苷类药物剂量图在碳青霉烯类耐药肠杆菌科引起的严重感染患者中选择泊沙康唑给药间隔的模拟应用。
Clin Ther. 2019 Aug;41(8):1453-1462. doi: 10.1016/j.clinthera.2019.04.038. Epub 2019 Jun 24.
3
Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.与碳青霉烯类耐药肠杆菌科感染的流行和治疗相关的因素：在三家三级保健医院进行的一项为期七年的回顾性研究。
Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. doi: 10.1186/s12941-018-0267-8.
4
Activity of Plazomicin Tested against Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides.2016-2017 年美国医院分离株检测普拉佐米星活性：不同折点标准对氨基糖苷类药物敏感性率的影响。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02418-19.
5
Colistin-resistant Enterobacteriaceae bacteraemia: real-life challenges and options.耐黏菌素肠杆菌科菌血症：现实生活中的挑战与应对选择
Clin Microbiol Infect. 2016 Feb;22(2):e9-e10. doi: 10.1016/j.cmi.2015.10.005. Epub 2015 Oct 23.
6
Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.黏菌素耐药肠杆菌科（包括 MCR-1 产生菌）对普拉佐米星的活性。
J Antimicrob Chemother. 2017 Oct 1;72(10):2787-2791. doi: 10.1093/jac/dkx239.
7
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.儿童碳青霉烯类耐药肠杆菌科感染的治疗。
J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):56-66. doi: 10.1093/jpids/piz085.
8
Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin.开发针对广泛耐药病原体的新型抗生素：普拉佐米星的案例
Clin Microbiol Infect. 2018 Dec;24(12):1231-1233. doi: 10.1016/j.cmi.2018.07.020. Epub 2018 Aug 1.
9
Once-Daily Plazomicin for Complicated Urinary Tract Infections.每日 1 次普拉唑米星治疗复杂性尿路感染。
N Engl J Med. 2019 Feb 21;380(8):729-740. doi: 10.1056/NEJMoa1801467.
10
Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.帕拉米韦对美国医院分离的革兰氏阴性和革兰氏阳性菌的活性及氨基糖苷类药物对碳青霉烯类耐药肠杆菌科和产碳青霉烯酶基因的分离株的比较活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00313-18. Print 2018 Aug.

引用本文的文献

1
Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections.利用一种新型双功能免疫疗法来利用内源性抗聚糖抗体治疗革兰氏阴性细菌感染。
J Immunol. 2025 Jul 1;214(7):1617-1629. doi: 10.1093/jimmun/vkaf055.
2
Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials.储备抗生素：克服监管批准试验所产生证据的局限性
Global Health. 2025 Apr 3;21(1):17. doi: 10.1186/s12992-025-01109-4.
3
Pneumonia: Recent Updates on Diagnosis and Treatment.
肺炎：诊断与治疗的最新进展
Microorganisms. 2025 Feb 27;13(3):522. doi: 10.3390/microorganisms13030522.
4
New antibiotics targeting Gram-negative bacilli.针对革兰氏阴性杆菌的新型抗生素。
Infez Med. 2025 Mar 1;33(1):4-14. doi: 10.53854/liim-3301-2. eCollection 2025.
5
Carbapenem-resistant Enterobacterales in solid organ transplant recipients.实体器官移植受者中的耐碳青霉烯类肠杆菌科细菌
Am J Transplant. 2025 Apr;25(4):848-859. doi: 10.1016/j.ajt.2024.10.020. Epub 2024 Nov 9.
6
Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.肺炎中的热点问题。2023 年第五届西班牙专家年会的反思。
Rev Esp Quimioter. 2024 Jun;37(3):221-251. doi: 10.37201/req/018.2024. Epub 2024 Mar 4.
7
Carbapenem-Resistant in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives.碳青霉烯类耐药菌引起的尿路感染：从生物学研究进展到新兴治疗选择。
Medicina (Kaunas). 2024 Jan 26;60(2):214. doi: 10.3390/medicina60020214.
8
Antimicrobial approach of abdominal post-surgical infections.腹部手术后感染的抗菌治疗方法。
World J Gastrointest Surg. 2023 Dec 27;15(12):2674-2692. doi: 10.4240/wjgs.v15.i12.2674.
9
Reviewing novel treatment options for carbapenem-resistant .回顾针对耐碳青霉烯类药物的新型治疗选择。
Expert Rev Anti Infect Ther. 2024 Jan-Jun;22(1-3):71-85. doi: 10.1080/14787210.2024.2303028. Epub 2024 Feb 12.
10
Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.碳青霉烯类耐药革兰氏阴性菌感染住院成年患者接受新型β-内酰胺类或β-内酰胺类/β-内酰胺酶抑制剂、多黏菌素或氨基糖苷类药物靶向治疗的患者中，急性肾损伤（AKI）的发生率及其对患者结局的影响。
J Antimicrob Chemother. 2024 Jan 3;79(1):82-95. doi: 10.1093/jac/dkad351.